文献速递炎症性肠病

英夫利西单抗暴露-反应关系及与溃疡性结肠炎患者内镜下愈合相关的阈值

Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-10-26

该研究分析2项英夫利西单抗对比安慰剂随机对照试验中484例活动性溃疡性结肠炎患者数据,用二室群体药代动力学模型计算基线清除率及浓度阈值。发现基线英夫利西单抗清除率与第8周Mayo内镜评分呈线性关系(P < .001),诱导和维持期药物浓度与短期及长期内镜下愈合相关,需基于这些参数个体化给药的干预性研究来证实改善患者结局。

要点

  • 基线英夫利西单抗清除率<0.397 L/d与第8周Mayo内镜评分≤1相关。
  • 第2周浓度≥18.6 μg/mL、第6周≥10.6 μg/mL、第8周≥34.9 μg/mL与第8周Mayo内镜评分≤1相关。
  • 第14周≥5.1 μg/mL、第30周≥2.3 μg/mL与第30周Mayo内镜评分≤1相关,第14周≥6.7 μg/mL、第30周≥3.8 μg/mL与第30周Mayo内镜评分0相关。

核心结论

  • 基线英夫利西单抗清除率及诱导和维持治疗期间的药物浓度与溃疡性结肠炎短期和长期内镜下愈合相关。

研究设计与样本

  • 分析2项英夫利西单抗对比安慰剂随机对照试验中484例活动性溃疡性结肠炎患者的数据。
  • 第0、8、30周有Mayo内镜评分,用二室群体药代动力学模型计算基线英夫利西单抗清除率。

主要发现

  • 基线英夫利西单抗清除率与第8周Mayo内镜评分呈线性关系(P < .001)。
  • 基线清除率<0.397 L/d与第8周Mayo内镜评分≤1相关。
  • 第2周浓度≥18.6 μg/mL、第6周≥10.6 μg/mL、第8周≥34.9 μg/mL与第8周Mayo内镜评分≤1相关。
  • 第14周浓度≥5.1 μg/mL、第30周≥2.3 μg/mL与第30周Mayo内镜评分≤1相关。
  • 第14周浓度≥6.7 μg/mL、第30周≥3.8 μg/mL与第30周Mayo内镜评分0相关。

关键数值与推荐

  • 基线清除率阈值<0.397 L/d对应第8周Mayo内镜评分≤1。
  • 第2周浓度阈值≥18.6 μg/mL、第6周≥10.6 μg/mL、第8周≥34.9 μg/mL对应第8周Mayo内镜评分≤1。
  • 第14周浓度阈值≥5.1 μg/mL、第30周≥2.3 μg/mL对应第30周Mayo内镜评分≤1。
  • 第14周浓度阈值≥6.7 μg/mL、第30周≥3.8 μg/mL对应第30周Mayo内镜评分0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Therapeutic drug monitoring might be used to personalize infliximab treatment of patients with ulcerative colitis (UC), although exposure thresholds associated with endoscopic healing are uncertain. We aimed to determine infliximab concentration thresholds associated with endoscopic outcomes during induction and maintenance therapy for patients with UC. METHODS: We analyzed data from 484 patients with active UC included in 2 randomized controlled trials of infliximab vs placebo. Mayo endoscopic scores (MES) were available from weeks 0, 8, and 30. A 2-compartment population pharmacokinetic model was used to calculate infliximab clearance at baseline. We tested the linear trend between baseline infliximab clearance and MES at week 8. Receiver operating curve analysis identified infliximab clearance and concentration thresholds with a maximum Youden index corresponding to a MES of 0 or ≤1. RESULTS: We found a linear relationship between baseline infliximab clearance and week 8 MES (P < .001); a threshold of <0.397 L/d was associated with week 8 MES ≤1. Infliximab concentrations ≥18.6 μg/mL at week 2, ≥10.6 μg/mL at week 6, and ≥34.9 μg/mL at week 8 were associated with a week 8 MES of ≤1. Infliximab concentrations ≥5.1 μg/mL at week 14 and ≥2.3 μg/mL at week 30 were associated with a week 30 MES of ≤1. Infliximab concentrations ≥6.7 μg/mL at week 14 and ≥3.8 μg/mL at week 30 were associated with a week 30 MES of 0. CONCLUSIONS: Baseline clearance of infliximab and drug concentrations during induction and maintenance infliximab therapy are associated with short- and long-term endoscopic healing. Interventional studies that incorporate individualized dosing based on these parameters are required to show improved patient outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vande Casteele N, Jeyarajah J, Jairath V, et al. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018. PMID: 30613004. doi:10.1016/j.cgh.2018.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。